Edition:
United States

Divya Grover

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

10:56am EDT

Axovant to pull plug on Alzheimer's drug after key study fails

Drug developer Axovant Sciences Ltd said it would stop testing its lead drug in Alzheimer's after it failed to meet the main goals of a late-stage trial, underlining the challenges in developing treatments for the memory-robbing disease.

Sep 25 2017

FDA declines to approve Intellipharma's opioid painkiller

Intellipharmaceutics International Inc, said on Monday the U.S. Food and Drug Administration (FDA) declined to approve its opioid painkiller in its current form, asking for more proof of the drug's ability to prevent abuse.

Sep 20 2017

Pfizer files suit against J&J over Remicade contracts

Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson, saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's new biosimilar.

Sep 18 2017

Costly drugs to weigh on U.S. employers' expenses in 2018: survey

U.S. employers are bracing for higher health care expenses in 2018 as spending on new drugs to treat diseases such as cancer, multiple sclerosis and hepatitis C is expected to rise more than 7 percent, according to consultancy firm Mercer.

Sep 14 2017

Pfizer, Astellas prostate cancer drug promising in late-stage trial

Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages.

Sep 06 2017

Sarepta's shares jump on new DMD drug's promising trial results

Sarepta Therapeutics Inc's shares surged on Wednesday after the results of a trial on its drug to treat a fatal muscle-wasting disease showed it had the potential to be more effective than the company's approved drug for the same disease.

Sep 05 2017

Device maker Teleflex boosts urology business with NeoTract buy

Medical device maker Teleflex Inc said on Tuesday it would buy privately held NeoTract Inc in its second billion-dollar deal in the past nine months, to strengthen its portfolio of urology devices.

Aug 07 2017

Tenet Healthcare cuts forecast on weak patient admissions

Tenet Healthcare Corp slashed its full-year forecasts and reported a bigger-than-expected quarterly loss as the U.S. hospital operator struggled with fewer patient admissions, sending its shares down about 11 percent after the bell.

Aug 04 2017

Lilly's acute migraine drug succeeds in late-stage study

Drugmaker Eli Lilly and Co said on Friday its acute migraine drug lasmiditan succeeded in a key late-stage study, setting the stage for U.S. regulatory approval.

Aug 02 2017

Molina to exit two Obamacare markets by year-end

Molina Healthcare Inc said on Wednesday it would stop selling Obamacare plans in Utah and Wisconsin, joining a slew of health insurers that have exited Obamacare markets amid uncertainty over the healthcare law.

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary